Metronidazole Polpharma

Metronidazole, the active ingredient in Metronidazole Polpharma, is a nitroimidazole presented as an intravenous solution for intravenous use. It treats anaerobic bacterial infections and certain protozoal infections in adults and children as prescribed.

GNH USA supplies Metronidazole Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Metronidazole is an antibiotic that targets anaerobic bacteria and susceptible protozoa. It is indicated for the following conditions: - Anaerobic bacterial infections: eradicates mixed‑flora infections in intra‑abdominal, skin and soft‑tissue sites. - Bacterial vaginosis: restores normal vaginal flora by eliminating Gardnerella species. - Trichomoniasis: eliminates Trichomonas vaginalis in genital infections. - Amoebiasis: treats intestinal and extra‑intestinal Entamoeba histolytica infections. - Clostridioides difficile infection: reduces toxin‑producing C. difficile in moderate to severe cases.

Metronidazole may cause a range of adverse reactions. Monitoring patients for both common and serious events is recommended.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Metallic taste: transient alteration in oral sensation. - Headache: occasional mild to moderate pain. - Diarrhea: loose stools, usually self‑limited.

Serious or Rare Side Effects: - Seizures: neurologic events requiring immediate medical attention. - Peripheral neuropathy: tingling or numbness in extremities, may be irreversible. - Severe allergic reaction: rash, angioedema, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin and mucous membrane involvement. - Hepatic toxicity: elevated liver enzymes or hepatitis.

Before initiating therapy, clinicians should consider several safety measures. - Renal function assessment: adjust dosing in impaired clearance. - Hepatic function monitoring: watch for signs of liver injury. - Alcohol avoidance: prevent disulfiram‑like reactions. - Pregnancy risk evaluation: use only when benefits outweigh potential risks. - Hypersensitivity screening: avoid in patients with known metronidazole allergy. - Store at below 25°C: keep in original packaging, protect from moisture and light.

Metronidazole can interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Alcohol: may cause severe flushing, tachycardia, and hypotension. - Warfarin: potentiates anticoagulant effect, increasing bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole plasma concentrations. - Cimetidine: can increase metronidazole levels, enhancing side effects. - Carbamazepine: may lower metronidazole exposure, reducing efficacy.